65,437 trials
Neovascular Age-Related Macular Degeneration
Primary: Change From Baseline at Week 48 in Best-Corrected Visual Acuity in Study Eye — 9.9; 10.9 Letters Read — p=0.006
Tuberculosis · Tuberculosis, Pulmonary
Primary: Number of Participants With Treatment-related Adverse Events — 0; 1; 1; 0 Participants
Metastatic or Locally-advanced Unresectable Breast Cancer
Primary: Phase II Dose of BYL719/Alpelisib (Arm A and Arm B) — 250; 250 mg
Generalized Moderate Chronic Periodontitis · Generalized Severe Chronic Periodontitis · Periodontal Diseases
Primary: Change in Clinical Attachment Level (CAL) — 3.5; 3.4 mm
Asthma
Primary: Change From Baseline in Serum 25OHD — 4.3; 9.6 nmol/L
Anxiety · Anxiety Disorders · Anxiety Generalized
Primary: Change in Anxiety: Depression Anxiety Stress Scale (DASS21). — 9.38; 10.1; 10.5; 9.85 units on a scale
Hypertension
Primary: Number of Participants Who Experienced At Least One Treatment-Emergent Adverse Event (TEAE) — 9 Participants
Preterm Birth
Primary: Neonatal Mortality Rate at 28 Days in <5th Percentile Birth Weight Infants (as a Proxy Measure for Prematurity) — 566; 524 Participants — p=0.65
Breast Cancer
Primary: Correlation of Peak Displacement (PD) for Detecting Malignancy — 4.5803; 8.628 microns — p=0.2988
Advanced Non-small Cell Lung Cancer (NSCLC)
Primary: Response Rate (Centrally Assessed) — 13.6; 19.6 percentage of participants
Acute Respiratory Failure
Primary: Incidence of Hypoxemia — 57; 118 Participants
Autism Spectrum Disorder
Primary: Change in Competitive Integrated Employment Rates — 12; 0 Participants
Major Depression
Primary: Medication Possession Ratio (MPR) During First 180 Days of Treatment — 0.47; 0.49; 0.46; 0.48 Ratio
Diabetes · Asthma · Chronic Obstructive Pulmonary Disease
Primary: Patient Activation — 61.87; 63.73; 63.82; 63.15 score on a scale — p=0.0211
Injury of Radial Artery
Primary: Radial Artery Occlusion — 13; 13; 10; 13 Participants